Gene Therapy Developer Sangamo Therapeutics Files for Chapter 11 Bankruptcy with Sale Plans
Key Insights
Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection in a strategic move to facilitate the sale of the company.
The gene therapy developer received initial court approval for $30 million in debtor-in-possession (DIP) financing to support operations during the restructuring process.
The bankruptcy filing and DIP financing are designed to preserve the company's gene therapy pipeline and platform while pursuing a going-concern sale.
Sangamo Therapeutics, a biotechnology company focused on genomic medicine and gene therapy development, has filed for Chapter 11 bankruptcy protection with plans to pursue a sale of the company. The filing marks a significant development for the gene therapy sector, as Sangamo has been a long-standing player in the field with its proprietary zinc finger nuclease (ZFN) gene-editing platform.
The company simultaneously secured initial court approval for $30 million in debtor-in-possession (DIP) financing, which will provide the necessary capital to maintain operations throughout the restructuring and sale process. DIP financing is a specialized form of funding available to companies undergoing Chapter 11 reorganization, allowing them to continue day-to-day activities, preserve asset value, and meet obligations to employees and critical vendors.
The Chapter 11 filing is structured as a strategic mechanism to maximize value for stakeholders while preserving Sangamo's scientific assets and ongoing programs. By entering bankruptcy with a pre-arranged sale framework, the company aims to identify a buyer capable of advancing its gene therapy pipeline and realizing the potential of its genomic medicine platform.
Sangamo's decision reflects the challenging financial environment facing many biotechnology companies, particularly those in the gene therapy space where high development costs, lengthy regulatory timelines, and complex manufacturing requirements create substantial capital demands. The $30 million DIP facility, approved on an interim basis by the bankruptcy court, is intended to bridge the company through the sale process without disruption to critical research and development activities.
The ultimate outcome of the sale process will determine whether Sangamo's gene therapy programs and proprietary technologies continue under new ownership. The company's platform and pipeline assets are expected to attract interest from both strategic acquirers and financial investors seeking to enter or expand their presence in the genomic medicine field.